ReviewJournal of clinical medicine2021
Treating Hyperuricemia: The Last Word Hasn't Been Said Yet.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.Clinical journal of the American Society of Nephrology : CJASN · 2022Trial
- Timing of urate-lowering therapy and risk of kidney failure and mortality in CKD: an application of the parametric G-formula.Clinical kidney journal · 2026Article
- Relationship of the intensity of physical performance and sedentary time with uric acid in patients with type 2 diabetes.Journal of diabetes investigation · 2025Article
- The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023Review
- Non-Haemodynamic Mechanisms Underlying Hypertension-Associated Damage in Target Kidney Components.International journal of molecular sciences · 2023Review
- Role of Uric Acid in Vascular Remodeling: Cytoskeleton Changes and Migration in VSMCs.International journal of molecular sciences · 2023Article
- Prevalence of Hyperuricemia and Its Association with Cardiovascular Risk Factors and Subclinical Target Organ Damage.Journal of clinical medicine · 2022Article
- Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?Clinical kidney journal · 2022Review
- Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022Article
- Uric acid and arterial stiffness in children and adolescents: Role of insulin resistance and blood pressure.Frontiers in cardiovascular medicine · 2022Article
- A Changing Perspective for Treatment of Chronic Kidney Disease.Journal of clinical medicine · 2021Article
- Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout as well as asymptomatic hyperuricemia have been associated with several traditional cardiovascular risk factors and chronic kidney disease. Both in vitro studies and animal models support a role for uric acid mediating both hemodynamic and tissue toxicity leading to glomerular and tubule-interstitial damage, respectively. Nevertheless, two recent well designed and carried out trials failed to show the benefit of allopurinol treatment on kidney outcomes, casting doubts on expectations of renal protection by the use of urate lowering treatment. With the aim of providing possible explanations for the lack of effect of urate lowering treatment on chronic kidney disease progression, we will critically review results from all available randomized controlled trials comparing a urate-lowering agent with placebo or no study medication for at least 12 months and report renal clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.